| الوصف: |
Background- Wuhan, Hubei's capital, reported severe pneumonia in December 2019. China reported the epidemic to the WHO on December 31, 2019, based on respiratory sample aetiology. SARS CoV-2 caused COVID-19. Confusion, depression, anxiety, memory loss, and insomnia are more common in COVID-19 patients. SARS (severe acute respiratory syndrome) infection has been linked to acute psychiatric symptoms, elevated inflammatory markers, and many neurologic manifestations in critically ill COVID-19 patients with comorbidities. Methods: After Institutional Ethics Committee approval, this prospective study was conducted in the Department of Medicine, MGM Medical College and M.Y.H. and Associated Hospitals, Indore. COVID-positive patients aged 18–80 who consented were included. Severity of covid-19 patients divided into two groups and neuropsychiatric manifestations were observed. Demographics, comorbidities, disease severity, neurological/psychiatric symptoms, and diagnoses were compared. Statistical analysis compared the groups. Results: A total of 300 patients were included in the study . The mean age of the patients was 50.8 ±10.2 years, and their mean BMI was 26.04 5.63 kg/m2. The patients fell into the COVID-19 mild 94 (31.30%) and moderate 206 (68.7%) severity categories. The neurological as well as psychiatric manifestation were seen more in moderately severe cases. Conclusion: Neurological/psychiatric symptoms are common in COVID-19 and can evolve over time. COVID-19's neuropsychiatric and neurological symptoms are expected to increase healthcare costs. Thus, treating these patients urgently requires recognition and familiarity with these neurological/psychiatric conditions |
